This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marty, F. M.
Right arrow Articles by Baden, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marty, F. M.
Right arrow Articles by Baden, L. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2006, p. 3450-3453, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00658-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Reactivity of (1->3)-ß-D-Glucan Assay with Commonly Used Intravenous Antimicrobials

Francisco M. Marty,1,2,3* Colleen M. Lowry,1 Steven J. Lempitski,4 David W. Kubiak,1 Malcolm A. Finkelman,4 and Lindsey R. Baden1,2,3

Brigham & Women's Hospital,1 Dana-Farber Cancer Institute,2 Harvard Medical School, Boston, Massachusetts,3 Associates of Cape Cod, Inc., East Falmouth, Massachusetts4

Received 30 May 2006/ Returned for modification 15 July 2006/ Accepted 31 July 2006


arrow
ABSTRACT
 
Forty-four intravenous antimicrobials were tested for the presence of (1->3)-ß-D-glucan (BG). Colistin, ertapenem, cefazolin, trimethoprim-sulfamethoxazole, cefotaxime, cefepime, and ampicillin-sulbactam tested positive for BG at reconstituted-vial concentrations but not when diluted to usual maximum plasma concentrations. False-positive BG assays may occur when some antimicrobials are administered; however, this needs to be confirmed.


arrow
TEXT
 
The Food and Drug Administration (FDA) approved the Glucatell assay (Associates of Cape Cod, Falmouth, MA) in 2004 as an aid in the diagnosis of deep-seated mycoses and fungemia (3, 10, 15). (1->3)-ß-D-Glucan (BG) is present in the cell walls of many pathogenic fungi, including Candida sp., Aspergillus sp., and Fusarium sp. (11).

Galactomannan detection by sandwich enzyme-linked immunosorbent assay (Platelia Aspergillus enzyme-linked immunosorbent assay; Bio-Rad Laboratories, Hercules, CA) was approved by the FDA as a diagnostic aid for the diagnosis of invasive aspergillosis in 2003 (2). Although the in vitro cross-reactivity of galactomannan with piperacillin-tazobactam had been reported (1, 18), it was only after marketing the assay that clinical false-positive results were observed (14, 17). This diminished the diagnostic utility of galactomannan detection in centers where piperacillin-tazobactam had become the empirical antibacterial treatment of febrile neutropenic patients.

False-positive BG results are known to occur in patients undergoing hemodialysis with cellulose membranes (5); patients treated with immunoglobulin, albumin (4, 12), or other blood products filtered through cellulose depth filters containing BG (9, 16); and patients with serosal exposure to glucan-containing gauze (6).

Given the potential for fungal cell wall elements or leachates from cellulosic materials to be present in antimicrobial preparations, we sought to determine the reactivity of the BG assay among intravenous antimicrobials available in the United States.

(This work was presented in part previously [F. M. Marty, C. M. Lowry, S. J. Lempitski, D. W. Kubiak, M. A. Findelman, and L. R. Baden, Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-163, 2005].)

Forty-four commercially available intravenous antimicrobial agents were tested for the presence of BG using the Glucatell assay (Table 1). An initial lot was tested for each agent, with the exception of piperacillin-tazobactam, for which three lots were tested. All drug samples were diluted or solubilized, as specified in the product's package insert, to yield reconstituted-vial concentrations (RVC). All diluents used in the reconstitution process were also tested. Once prepared, samples were coded, placed in BG-free vials, frozen to –80°C, and shipped for analysis to Beacon Diagnostics Laboratory (East Falmouth, MA), where all samples were tested in a blind fashion.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Antimicrobials, manufacturers, and lots tested

Briefly, 25 µl of drug sample at the RVC was added to wells in duplicate. One hundred microliters of Glucatell reagent was added to the wells. The sample and reagent were incubated at 37°C, using a time-of-onset kinetic assay (as described in the product insert). Samples that demonstrated inhibition of the reaction at RVC were serially diluted in glucan-free water. Analysis was performed using a log-log plot of time to onset versus standard concentration (pachyman). Duplicate samples were spiked with a positive control reagent. A spike recovery of 50 to 200% was required for a valid test result.

RVC drug solutions that tested positive or inhibited the BG reaction when diluted to concentrations above the drug infusate concentration (DIC) were retested at the DIC and maximum plasma concentrations (MPC) as directed in the package insert or scientific literature (Table 1). Further lots of those antimicrobials that tested positive or inhibited the BG reaction were analyzed for reproducibility. All these samples were prepared and tested in a blind fashion.

Seven antimicrobial agents tested positive for BG at the RVC: colistin, ertapenem, cefazolin (in vials), trimethoprim-sulfamethoxazole, cefotaxime, cefepime, and ampicillin-sulbactam in decreasing order (Table 2). BG was detected in additional lots of these antimicrobials at the RVC, with the exception of ampicillin-sulbactam, of which two additional lots were nonreactive. Colistin, ertapenem, cefotaxime, and cefepime had detectable BG at concentrations greater than 80 pg/ml when diluted to the DIC; two lots of colistin inhibited the reaction and needed to be diluted 500-fold in order to obtain a valid result at the DIC. Although all lyophilized cefazolin vials had detectable BG at the RVC, no premixed cefazolin bag lots from a different manufacturer had detectable BG. None of the seven agents tested positive for BG when diluted to concentrations representing the MPC. Diluents and products used in the transfer of drug did not have detectable BG levels. Several antimicrobials inhibited the BG assay at the RVC, but only azithromycin, pentamidine, and colistin remained highly inhibitory at the DIC (Table 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2. BG content of intravenous antimicrobialsa

The availability of noninvasive diagnostic tests for the detection of invasive fungal infections (IFI) is an important advance in the management of such infections (13). As therapeutic decisions may be made based on the results of these tests, it is important to understand their potential limitations.

BG was detected in 7 of the 44 antimicrobial agents at RVC. BG was still detected in four of seven of these antimicrobials at DICs that are above the current positivity threshold for the assay. BG positivity was consistent among different antimicrobial lots, except with ampicillin-sulbactam. Some antimicrobials caused optical artifacts or inhibited the BG assay at high concentrations. Although not available in the United States, intravenous amoxicillin-clavulanic acid was found to contain high BG levels and to cause false-positive results after clinical administration (8).

There was no obvious antimicrobial class effect in terms of the BG reactivity. No antimicrobial solution had detectable BG at the usual drug MPC, but this should be interpreted with caution. As learned from the galactomannan enzyme-linked immunosorbent assay cross-reactivity experience with piperacillin-tazobactam administration (7, 17, 18), the false-positive results were not due to detection of the antimicrobial itself but to the introduction of galactofuran in the manufacturing process, which has a pharmacokinetic behavior different than that of the antimicrobial itself (18).

The findings of BG content cannot be generalized to products produced by manufacturers other than those tested (Table 1). There can be lot-to-lot variability in BG content, as in the case of galactomannan (7), so additional periodic testing of antimicrobial lots commonly used in patients at risk for IFI may be warranted, especially if unexplained BG results are encountered. Interestingly, no piperacillin-tazobactam lots tested positive for BG. This may allow centers that use piperacillin-tazobactam for empirical febrile neutropenia therapy the possibility of using BG for noninvasive surveillance and diagnosis of IFI.

There is limited reactivity between the BG assay and most commonly used intravenous antimicrobial agents. Caution should be used in interpreting BG assay results for drug preparations that do contain BG, as the kinetics of BG are not yet defined. Validation of these findings and correlation with clinical samples are warranted.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Division of Infectious Diseases, Brigham & Women's Hospital, 75 Francis Street, PBB-A4, Boston, MA 02115. Phone: (617) 732-8881. Fax: (617) 732-6829. E-mail: fmarty{at}partners.org. Back


arrow
REFERENCES
 
    1
  1. Ansorg, R., R. van den Boom, and P. M. Rath. 1997. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 40:353-357.[Medline]
    2. 2
  2. Evaluation and Safety Center for Devices and Radiological Health, FDA. 16 May 2003, posting date. Bio-Rad Laboratories Platelia® Aspergillus EIA. [Online.] http://www.fda.gov/cdrh/pdf2/k023857.pdf. Accessed 16 March 2006.
    3. 3
  3. Evaluation and Safety Center for Devices and Radiological Health, FDA. 21 May 2004, posting date. Glucatell (1-3-beta-D-glucan serological assay). [Online.] http://www.fda.gov/cdrh/pdf3/K032373.pdf. Accessed 20 December 2005.
    4. 4
  4. Ikemura, K., K. Ikegami, T. Shimazu, T. Yoshioka, and T. Sugimoto. 1989. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J. Clin. Microbiol. 27:1965-1968.[Abstract/Free Full Text]
    5. 5
  5. Kanda, H., K. Kubo, K. Hamasaki, Y. Kanda, A. Nakao, T. Kitamura, T. Fujita, K. Yamamoto, and T. Mimura. 2001. Influence of various hemodialysis membranes on the plasma (1->3)-beta-D-glucan level. Kidney Int. 60:319-323.[CrossRef][Medline]
    6. 6
  6. Kimura, Y., A. Nakao, H. Tamura, S. Tanaka, and H. Takagi. 1995. Clinical and experimental studies of the limulus test after digestive surgery. Surg. Today 25:790-794.[CrossRef][Medline]
    7. 7
  7. Machetti, M., E. Furfaro, and C. Viscoli. 2005. Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob. Agents Chemother. 49:3984-3985.[Free Full Text]
    8. 8
  8. Mennink-Kersten, M. A., A. Warris, and P. E. Verweij. 2006. 1,3-Beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N. Engl. J. Med. 354:2834-2835.[Free Full Text]
    9. 9
  9. Nagasawa, K., T. Yano, G. Kitabayashi, H. Morimoto, Y. Yamada, A. Ohata, M. Usami, and T. Horiuchi. 2003. Experimental proof of contamination of blood components by (1->3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J. Artif. Organs 6:49-54.[CrossRef][Medline]
    10. 10
  10. Odabasi, Z., G. Mattiuzzi, E. Estey, H. Kantarjian, F. Saeki, R. J. Ridge, P. A. Ketchum, M. A. Finkelman, J. H. Rex, and L. Ostrosky-Zeichner. 2004. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39:199-205.[CrossRef][Medline]
    11. 11
  11. Odabasi, Z., V. L. Paetznick, J. R. Rodriguez, E. Chen, M. R. McGinnis, and L. Ostrosky-Zeichner. 2006. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med. Mycol. 44:267-272.[CrossRef][Medline]
    12. 12
  12. Ogawa, M., H. Hori, S. Niiguchi, E. Azuma, and Y. Komada. 2004. False-positive plasma (1->3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int. J. Hematol. 80:97-98.[CrossRef][Medline]
    13. 13
  13. Patterson, T. F. 2005. Advances and challenges in management of invasive mycoses. Lancet 366:1013-1025.[CrossRef][Medline]
    14. 14
  14. Sulahian, A., S. Touratier, and P. Ribaud. 2003. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N. Engl. J. Med. 349:2366-2367.[Free Full Text]
    15. 15
  15. Takaki, Y., N. Seki, S. Kawabata Si, S. Iwanaga, and T. Muta. 2002. Duplicated binding sites for (1->3)-beta-D-glucan in the horseshoe crab coagulation factor G: implications for a molecular basis of the pattern recognition in innate immunity. J. Biol. Chem. 277:14281-14287.[Abstract/Free Full Text]
    16. 16
  16. Usami, M., A. Ohata, T. Horiuchi, K. Nagasawa, T. Wakabayashi, and S. Tanaka. 2002. Positive (1->3)-beta-D-glucan in blood components and release of (1->3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion 42:1189-1195.[CrossRef][Medline]
    17. 17
  17. Viscoli, C., M. Machetti, P. Cappellano, B. Bucci, P. Bruzzi, M. T. Van Lint, and A. Bacigalupo. 2004. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin. Infect. Dis. 38:913-916.[CrossRef][Medline]
    18. 18
  18. Walsh, T. J., S. Shoham, R. Petraitiene, T. Sein, R. Schaufele, A. Kelaher, H. Murray, C. Mya-San, J. Bacher, and V. Petraitis. 2004. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J. Clin. Microbiol. 42:4744-4748.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, October 2006, p. 3450-3453, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00658-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S., Sulahian, A. (2008). Contribution of the (1->3)-{beta}-D-Glucan Assay for Diagnosis of Invasive Fungal Infections. J. Clin. Microbiol. 46: 1009-1013 [Abstract] [Full Text]  
  • Kikkert, R., Bulder, I., de Groot, E. R., Aarden, L. A., Finkelman, M. A. (2007). Potentiation of Toll-like receptor-induced cytokine production by (1->3)-{beta}-D-glucans: implications for the monocyte activation test. Innate Immunity 13: 140-149 [Abstract]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marty, F. M.
Right arrow Articles by Baden, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marty, F. M.
Right arrow Articles by Baden, L. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»